Evidence map›Paper›PMID 37112877›Full record

ArticleViruses2023

Targeting the HIV-1 and HBV Capsids, an EnCore.

William M McFadden, Stefan G Sarafianos

Abstract readEditorial
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. A Tag-Free Platform for Synthesis and Screening of Cyclic Peptide Libraries.Angewandte Chemie (International ed. in English) · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

William M McFaddenCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-6911-2172
Stefan G SarafianosCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Structural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Karen A Kirby · 2022 to 2026
$36.7M
Structural studies of HIV Capsid with host factors and Capsid-targeting antiviralsR01AI120860 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI Stefan G Sarafianos, Zhengqiang Wang · 2015 to 2026
$6.0M
HBV Capsid EffectorsR01AI132833 · NIAID · EMORY UNIVERSITY · PI Raymond Felix Schinazi · 2017 to 2026
$5.3M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM135060 · NIGMS · EMORY UNIVERSITY · PI Lawrence H. Boise, ANITA H. CORBETT · 2020 to 2026
$2.8M
Structural and Biochemical Effects of Capsid-targeting Molecules on HIV-1 Capsid AssemblyF31AI174951 · NIAID · EMORY UNIVERSITY · PI WILLIAM MICHAEL MCFADDEN · 2023 to 2026
$196k
NIAID NIH HHS F31 AI174951NIAID NIH HHS R01 AI120860NIAID NIH HHS R01 AI132833NIAID NIH HHS U54 AI170855NIGMS NIH HHS T32 GM135060
6 · The paper itself

Abstract

Not many structures are common among all viruses: only nucleic acid and a protein coat [...].

Indexed as

CapsidHIV-1Capsid ProteinsHepatitis B virusLactic AcidCapsid ProteinsLactic Acid

Identifiers

PMID37112877
PMCPMC10146275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.